Boehringer Ingelheim acquires Global Stem cell Technology

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal HealthBoehringer Ingelheim joins forces with Belgian biotech company GST which develops and produces state-of-the art stem cell products for horses and petsThe acquisition follows two years of successful partnership that brought the first-ever registered stem cell-based veterinary medicine to the European marketDecision to acquire GST is fully aligned with part of Boehringer Ingelheim ’s Animal Health strategy, aiming to strengthen its portfolio capabilities to accelerate innovation and growth
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news